<DOC>
	<DOCNO>NCT02621892</DOCNO>
	<brief_summary>This phase 3 , 12-week , randomize , double-blind , placebo-controlled , multi-center study evaluate safety efficacy tenapanor subject constipation-predominant irritable bowel syndrome ( IBS-C ) define ROME III criterion active disease determine two-week screening period . Subjects qualify randomize study either receive 50mg BID tenapanor placebo BID 12 week treatment period undergo 4 week placebo control randomize withdrawal .</brief_summary>
	<brief_title>A 12-Week Study With 4-Week Randomized Withdrawal Period Evaluate Efficacy Safety Tenapanor Treatment IBS-C</brief_title>
	<detailed_description>During 12-week treatment period , subject record daily assessment include : frequency time bowel movement ; sensation complete bowel emptying ; consistency bowel movement ; degree straining , worst abdominal pain , abdominal discomfort , abdominal bloating , abdominal fullness abdominal cramping . Subjects also record weekly assessment include : adequate relief IBS severity , constipation severity . At end 12-week treatment period , 4-week randomize withdrawal period subject complete study Tenapanor group randomize either Tenapanor 50mg BID placebo BID ( 1:1 ) subject complete study placebo group assign receive Tenapanor 50mg BID .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>18 75 year old Females must nonchildbearing potential ; If childbearing potential , must negative pregnancy test confirm use one appropriate mean contraception . Males must agree use appropriate method barrier contraception document surgical sterilization Subject meet definition IBSC use Rome III Criteria Diagnosis IBS A colonoscopy base AGA guideline ; every 10 year â‰¥ 50 year old , occurrence warning sign Functional diarrhea define Rome III criterion IBS diarrhea ( IBSD ) , mixed IBS ( IBSM ) , unsubtyped IBS define Rome III criterion Diagnosis treatment clinically symptomatic biochemical structural abnormality GI tract within 6 month prior screen , active disease within 6 month prior screen ; include limited cancer , inflammatory bowel disease , diverticulitis , duodenal ulcer , erosive esophagitis , gastric ulcer , pancreatitis ( within 12 month screen ) , cholelithiasis , amyloidosis , ileus , noncontrolled GERD , gastrointestinal obstruction , ischemic colitis carcinoid syndrome . Subject history current evidence laxative abuse ( clinical judgment physician ) Hepatic dysfunction ( ALT [ SGPT ] AST [ SGOT ] &gt; 2.5 time upper limit normal ) renal impairment ( serum creatinine &gt; 2mg/dL ) Any evidence treatment malignancy ( localize basal cell , squamous cell skin cancer cancer situ resect ) within previous year Any surgery stomach , small intestine colon , exclude appendectomy cholecystectomy ( unless within 60 day screen visit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>